Spots Global Cancer Trial Database for Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Official Title: Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer
Study ID: NCT00193271
Conditions
Study Description
Brief Summary: This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
Detailed Description: Upon determination of eligibility, patients will receive: Docetaxel + Estramustine
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Contact Details
Name: Anthony A. Meluch, MD
Affiliation: SCRI Development Innovations, LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
